Junctional epidermolysis bullosa ( JEB) is a variant of EB where the cleavage plane is in the lamina lucida of the epidermal basement membrane. The usually lethal form of JEB is called JEB-Herlitz.

Tampere University has licensed a drug molecule intended for treating Epidermolysis Bullosa (EB), a group of rare and severe skin disorders, to Theravia, a pharmaceutical company headquartered in the ...

its drug for rare and debilitating skin disease epidermolysis bullosa (EB). Shares in the Ireland-based rare disease specialist fell sharply after news of the complete response letter (CRL ...

Oleogel-S10 is an effective and well-tolerated long-term treatment for epidermolysis bullosa, including patients with severe forms of the disease.

Chaffaux, S., Taourit, S. & Guerin, G. A mutation in the LAMC2 gene causes the Herlitz junctional epidermolysis bullosa (H-JEB) in two French draft horse breeds. Genet. Sel. Evol. 35(2), 249–256 ...

A JERSEY student has braved the shave to raise money for charity in memory of her older brother, who died at just 19 weeks ...

RLF-TD011 has previously received orphan drug designation (ODD) from the U.S. Food and Drug Administration (FDA) for the treatment of EB. The Company also intends to seek qualified infectious disease ...

Long-term treatment with Oleogel-S10 (birch bark extract, Filsuvez) gel significantly reduced wound burden and disease activity in individuals with epidermolysis bullosa (EB), with a high ...

Filsuvez topical gel treats wounds associated with dystrophic as well as junctional epidermolysis bullosa in adults and in paediatric patients six months of age and above. "Edenbridge selects ...